Literature DB >> 2338751

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

S M Haffner1, M P Stern, H P Hazuda, B D Mitchell, J K Patterson.   

Abstract

Although type II diabetes is associated with both microvascular and macrovascular complications, duration of diabetes and severity of glycemia are strongly associated only with the former. Since prediabetic individuals are hyperinsulinemia, and since hyperinsulinemia may be a cardiovascular risk factor, we hypothesized that prediabetic individuals might have an atherogenic pattern of risk factors even before the onset of clinical diabetes, thereby explaining the relative lack of an association of macrovascular complications with either glycemic severity or disease duration. We documented the cardiovascular risk factor status of 614 initially nondiabetic Mexican Americans who later participated in an 8-year follow-up of the San Antonio Heart Study, a population-based study of diabetes and cardiovascular disease. Individuals who were nondiabetic at the time of baseline examination, but who subsequently developed type II diabetes (ie, confirmed prediabetic subjects, n = 43), had higher levels of total and low-density lipoprotein cholesterol, triglyceride, fasting glucose and insulin, 2-hour glucose, body mass index, and blood pressure, and lower levels of high-density lipoprotein cholesterol than subjects who remained nondiabetic (n = 571). Most of these differences persisted after adjustment for obesity and/or level of glycemia, but were abolished after adjustment for fasting insulin concentration. When subjects with impaired glucose tolerance at baseline (n = 106) were eliminated, the more atherogenic pattern of cardiovascular risk factors was still evident (and statistically significant) among initially normoglycemic prediabetic subjects. These results indicate that prediabetic subjects have an atherogenic pattern of risk factors (possibly caused by obesity, hyperglycemia, and especially hyperinsulinemia), which may be present for many years and may contribute to the risk of macrovascular disease as much as the duration of clinical diabetes itself.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338751     DOI: 10.1001/jama.263.21.2893

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  186 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Genetic determinants of diabetes and atherosclerosis.

Authors:  Braxton D Mitchell; Ikhide G Imumorin
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

3.  The cost of diabetes Type II in Europe: the CODE-2 Study.

Authors:  M Massi-Benedetti
Journal:  Diabetologia       Date:  2002-05-24       Impact factor: 10.122

Review 4.  Endothelial dysfunction and the metabolic syndrome.

Authors:  Gary E McVeigh; Jay N Cohn
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

5.  Long term follow up of women who have had gestational diabetes.

Authors:  T A Holt
Journal:  Br J Gen Pract       Date:  1992-09       Impact factor: 5.386

6.  Potential national and state medical care savings from primary disease prevention.

Authors:  Barbara A Ormond; Brenda C Spillman; Timothy A Waidmann; Kyle J Caswell; Bogdan Tereshchenko
Journal:  Am J Public Health       Date:  2010-11-18       Impact factor: 9.308

7.  Normal fasting plasma glucose predicts type 2 diabetes and cardiovascular disease in elderly population in Taiwan.

Authors:  C-L Huang; H-W Chang; J-B Chang; J-H Chen; J-D Lin; C-Z Wu; D Pei; Y-J Hung; C-H Lee; Y-L Chen; C-H Hsieh
Journal:  QJM       Date:  2015-11-16

8.  The Look AHEAD Trial: A Review and Discussion Of Its Outcomes.

Authors:  Xavier Pi-Sunyer
Journal:  Curr Nutr Rep       Date:  2014-12

Review 9.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

Review 10.  Epidemiology of the insulin resistance syndrome.

Authors:  James B Meigs
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.